top of page

Therapeutic potential of drug interventions on microglia in ALS

Dr. Susanne Petri, Hannover Medical School, Department of Neurology, in Hannover, Germany presented progress on her project “Therapeutic potential of drug interventions on microglia in ALS” to the NDR scientific group. She is investigating two compounds, Naringenin (a citrus flavonoid) and Parthenolide (from the Feverfew plant), two compounds that have shown positive effects in Alzheimer’s disease/ Parkinson’s disease and stroke/neuropathy, respectively. She uses primary cultures, the SOD1 mouse model, and ALS patient-derived iPSC’s to determine the effects of treatment. She has reported some of her results and are under review in the Journal of Neuroscience Research (2023 Thau-Habermann et al). Overall, the treatments are not cytotoxic and have a positive impact on microglial markers with a beneficial impact on motor neuron survival. Her work using these compounds in the SOD1 mouse model are ongoing, but preliminary results are promising. The results of her experiments bring hope to ALS patients by providing data supporting non-toxic and readily available treatments that are neuroprotective and could rescue dysregulated microglial and astrocytes, cells that are involved in the pathogenesis of ALS.

20 views0 comments

Recent Posts

See All

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study will wrap up in a few months and the Phase 2 will start, it will

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained


We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found


bottom of page